Jayamas Medica (OMED) Records Sales of Rp 2.06 Trillion and Profit of Rp 368.9 Billion

PT Jayamas Medica Industri Tbk (OMED) posted solid financial performance throughout the 2025 fiscal year, with sustained growth in sales and net profit amid the dynamics of the healthcare industry and global geopolitical pressures.

The company recorded net sales of Rp 2.06 trillion, up 9.4% year-on-year (YoY) from Rp 1.89 trillion in 2024.

In line with that, gross profit grew 15.0% YoY to Rp 717.5 billion, with the gross profit margin rising to 34.8% from 33.1% previously.

OMED also recorded operating profit of Rp 390.9 billion, up 12.2% YoY, with an operating margin of 18.9%.

Meanwhile, profit for the year increased 13.9% YoY to Rp 368.9 billion from Rp 324.0 billion the previous year.

In line with the profit growth, earnings per share (EPS) also rose to Rp 13.57 from Rp 11.89.

Disposable and consumable medical products remained the largest contributor, accounting for around 48.8% of total revenue, growing 9.4% YoY.

The wound care segment recorded growth of 16.2% YoY, driven by increased sales volume and the launch of the new Isoplast product.

The antiseptic and dialysis segment also grew 9.6% YoY in line with rising sales volume and product innovation.

“This performance reflects the stability of OMED’s business model, supported by a diversified product portfolio and extensive distribution network across Indonesia,” said Louis in a press statement on Thursday (26/3/2026).

Entering 2026, OMED maintains a positive outlook on the prospects of the national medical equipment industry, although it is still overshadowed by geopolitical uncertainty and potential energy price pressures.

The company targets revenue of around Rp 2.3 trillion in 2026, or growth of 10-15% YoY.

“This target will be supported by strengthening domestic distribution, developing products with higher margins, export market expansion, and sustainable operational efficiency improvements,” Louis added.